
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1990352/publications.pdf Version: 2024-02-01



HELLHADVALA

#	Article	IF	CITATIONS
1	Effect of Convalescent Plasma on Organ Support–Free Days in Critically III Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	3.8	169
2	Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. Journal of Clinical Virology, 2018, 101, 11-17.	1.6	161
3	Parechoviruses in children: understanding a new infection. Current Opinion in Infectious Diseases, 2010, 23, 224-230.	1.3	128
4	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Research, 2020, 5, 181.	0.9	122
5	Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications, 2020, 11, 6385.	5.8	103
6	Comparison of human parechovirus and enterovirus detection frequencies in cerebrospinal fluid samples collected over a 5â€year period in edinburgh: HPeV type 3 identified as the most common picornavirus type. Journal of Medical Virology, 2011, 83, 889-896.	2.5	100
7	High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. Journal of Medical Virology, 2013, 85, 893-898.	2.5	94
8	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Research, 2020, 5, 181.	0.9	81
9	Molecular epidemiology and evolution of coxsackievirus A9. Microbiology (United Kingdom), 2000, 81, 1361-1372.	0.7	79
10	Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infectious Diseases, The, 2020, 20, 350-361.	4.6	76
11	Convalescent plasma therapy for the treatment of patients with COVIDâ€19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfusion Medicine, 2021, 31, 167-175.	0.5	71
12	Detection and Genetic Characterization of Enteroviruses Circulating among Wild Populations of Chimpanzees in Cameroon: Relationship with Human and Simian Enteroviruses. Journal of Virology, 2011, 85, 4480-4486.	1.5	65
13	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Eurosurveillance, 2020, 25, .	3.9	64
14	Genetics, Recombination and Clinical Features of Human Rhinovirus Species C (HRV-C) Infections; Interactions of HRV-C with Other Respiratory Viruses. PLoS ONE, 2009, 4, e8518.	1.1	62
15	Genetic characterization of human coxsackievirus A6 variants associated with atypical hand, foot and mouth disease: a potential role of recombination in emergence and pathogenicity. Journal of General Virology, 2015, 96, 1067-1079.	1.3	55
16	Variability and pathogenicity of hepatitis E virus genotype 3 variants. Journal of General Virology, 2015, 96, 3255-3264.	1.3	54
17	Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Eurosurveillance, 2020, 25, .	3.9	53
18	Distinct systemic and central nervous system disease patterns in enterovirus and parechovirus infected children. Journal of Infection, 2014, 69, 69-74.	1.7	50

#	Article	IF	CITATIONS
19	Environmental Surveillance Reveals Complex Enterovirus Circulation Patterns in Human Populations. Open Forum Infectious Diseases, 2018, 5, ofy250.	0.4	47
20	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infectious Diseases, 2021, 21, 1170.	1.3	46
21	Development and Assay of RNA Transcripts of Enterovirus Species A to D, Rhinovirus Species A to C, and Human Parechovirus: Assessment of Assay Sensitivity and Specificity of Real-Time Screening and Typing Methods. Journal of Clinical Microbiology, 2012, 50, 2910-2917.	1.8	44
22	Rapid Simultaneous Detection of Enterovirus and Parechovirus RNAs in Clinical Samples by One-Step Real-Time Reverse Transcription-PCR Assay. Journal of Clinical Microbiology, 2011, 49, 2620-2624.	1.8	43
23	Emergence of a novel subclade of influenza A(H3N2) virus in London, December 2016 to January 2017. Eurosurveillance, 2017, 22, .	3.9	42
24	Recommendations for the introduction of metagenomic high-throughput sequencing in clinical virology, part I: Wet lab procedure. Journal of Clinical Virology, 2021, 134, 104691.	1.6	42
25	The need for treatment against human parechoviruses: how, why and when?. Expert Review of Anti-Infective Therapy, 2010, 8, 1417-1429.	2.0	38
26	The importance of enterovirus surveillance in a post-polio world. Lancet Infectious Diseases, The, 2022, 22, e35-e40.	4.6	38
27	Epidemiology and clinical characteristics of parainfluenza virus 3 outbreak in a Haemato-oncology unit. Journal of Infection, 2012, 65, 246-254.	1.7	35
28	Increase in Enterovirus D68 Infections in Young Children, United Kingdom, 2006–2016. Emerging Infectious Diseases, 2019, 25, 1200-1203.	2.0	35
29	Strategies to improve detection and management of human parechovirus infection in young infants. Lancet Infectious Diseases, The, 2019, 19, e51-e58.	4.6	35
30	Co-circulation of enteroviruses between apes and humans. Journal of General Virology, 2014, 95, 403-407.	1.3	33
31	Surveillance and laboratory detection for non-polio enteroviruses in the European Union/European Economic Area, 2016. Eurosurveillance, 2017, 22, .	3.9	33
32	Mapping of tissue tropism determinants in coxsackievirus genomes. Journal of General Virology, 2002, 83, 1697-1706.	1.3	32
33	Tissue tropism of recombinant coxsackieviruses in an adult mouse model. Journal of General Virology, 2005, 86, 1897-1907.	1.3	31
34	SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Eurosurveillance, 2021, 26, .	3.9	31
35	Comparability of six different immunoassays measuring SARS oV â€2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction. Transfusion, 2021, 61, 2837-2843.	0.8	29
36	Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020. Eurosurveillance, 2020, 25, .	3.9	28

#	Article	IF	CITATIONS
37	Understanding the outcomes of COVID-19 – does the current model of an acute respiratory infection really fit?. Journal of General Virology, 2021, 102, .	1.3	25
38	Acute viral hepatitis – Should the current screening strategy be modified?. Journal of Clinical Virology, 2014, 59, 184-187.	1.6	24
39	High Seroprevalence of Enterovirus Infections in Apes and Old World Monkeys. Emerging Infectious Diseases, 2012, 18, 283-286.	2.0	20
40	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. Journal of Infectious Diseases, 2021, 224, 595-605.	1.9	20
41	Hepatitis B infections among blood donors in <scp>England</scp> between 2009 and 2018: Is an occult hepatitis B infection a risk for blood safety?. Transfusion, 2021, 61, 2402-2413.	0.8	19
42	Role of Sequencing the Measles Virus Hemagglutinin Gene and Hypervariable Region in the Measles Outbreak Investigations in Sweden During 2013–2014. Journal of Infectious Diseases, 2016, 213, 592-599.	1.9	18
43	Molecular Epidemiology and Evolutionary Trajectory of Emerging Echovirus 30, Europe. Emerging Infectious Diseases, 2021, 27, 1616-1626.	2.0	18
44	European Non-Polio Enterovirus Network: Introduction of Hospital-Based Surveillance Network to Understand the True Disease Burden of Non-Polio Enterovirus and Parechovirus Infections in Europe. Microorganisms, 2021, 9, 1827.	1.6	18
45	Case report: Eastern equine encephalitis virus imported to the UK. Journal of Medical Virology, 2009, 81, 305-308.	2.5	17
46	Convalescent plasma therapy for persistent hepatitis E virus infection. Journal of Hepatology, 2019, 71, 434-438.	1.8	17
47	Evaluation of SARSâ€CoVâ€2 antibody titers and potency for convalescent plasma donation: a brief commentary. Vox Sanguinis, 2021, 116, 493-496.	0.7	17
48	Cardiomyocyte Apoptosis after Antiviral WIN 54954 Treatment in Murine Coxsackievirus B3 Myocarditis. Scandinavian Cardiovascular Journal, 2002, 36, 187-192.	0.4	16
49	Epidemiology of Campylobacter jejuni infections in Sweden, November 2011–October 2012: is the severity of infection associated with C. jejuni sequence type?. Infection Ecology and Epidemiology, 2016, 6, 31079.	0.5	16
50	Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials. Critical Care, 2020, 24, 449.	2.5	16
51	Pathogenesis of coxsackievirus A9 in mice: role of the viral arginine-glycine-aspartic acid motif. Journal of General Virology, 2003, 84, 2375-2379.	1.3	15
52	High Rates of Infection with Novel Enterovirus Variants in Wild Populations of Mandrills and Other Old World Monkey Species. Journal of Virology, 2014, 88, 5967-5976.	1.5	15
53	Seroprevalence and Virologic Surveillance of Enterovirus 71 and Coxsackievirus A6, United Kingdom, 2006–2017. Emerging Infectious Diseases, 2021, 27, 2261-2268.	2.0	15
54	Pathogenicity of individual rhinovirus species during exacerbations of cystic fibrosis. European Respiratory Journal, 2015, 45, 1748-1751.	3.1	14

#	Article	IF	CITATIONS
55	Viral meningitis: epidemiology and diagnosis. Lancet Infectious Diseases, The, 2016, 16, 1211-1212.	4.6	11
56	Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. Sexually Transmitted Infections, 2022, 98, 132-135.	0.8	10
57	Convalescent plasma donors show enhanced crossâ€reactive neutralizing antibody response to antigenic variants of SARSâ€CoVâ€2 following immunization. Transfusion, 2022, 62, 1347-1354.	0.8	9
58	Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma. Journal of Infectious Diseases, 2022, 225, 971-976.	1.9	5
59	Convalescent plasma for <scp>COVID</scp> â€19: Donor demographic factors associated high neutralising antibody titres. Transfusion Medicine, 2022, 32, 327-337.	0.5	5
60	Detection frequencies and viral load distribution of parvovirus <scp>B19 DNA</scp> in blood and plasma donations in <scp>E</scp> ngland. Transfusion Medicine, 2022, 32, 402-409.	0.5	4
61	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, .	1.9	3
62	Lessons learnt from syphilis-infected blood donors: a timely reminder of missed opportunities. Sexually Transmitted Infections, 2021, , sextrans-2021-055034.	0.8	2
63	Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom's COVID-19 Public Health Response. Microbiology Spectrum, 2022, 10, e0228921.	1.2	2
64	Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020. Journal of Global Health, 2021, 11, 05014.	1.2	1
65	Evaluation of the national laboratory-based surveillance system for respiratory syncytial virus in Sweden, 2015–2016. Journal of Clinical Virology, 2018, 104, 11-15.	1.6	0
66	Bitten in the Hampshires. , 2019, , 145-148.		0
67	Comparison of <scp>SARSâ€CoV</scp> â€2 neutralizing antibody testing of convalescent plasma donations in the Netherlands and England: A pilot study. Health Science Reports, 2021, 4, e439.	0.6	0
68	Blood donor notification of variant Creutzfeldt–Jakob disease risk: Lessons in communicating donor deferral and risk. Transfusion Medicine, 0, , .	0.5	0